You just read:

ContraVir to Highlight Clinical Data from Ongoing Phase 2a Study of Tenofovir Exalidex (TXL™) for Treating Hepatitis B

News provided by

ContraVir Pharmaceuticals, Inc.

Feb 14, 2017, 06:00 ET